Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
CYBN Cybin
0.440-0.020-4.35%
Close
02/03 16:00 ET
0.450+0.010+2.20%
Post Mkt Price 02/03 19:56 ET
High
0.469
Open
0.455
Turnover
717.83K
Low
0.400
Pre Close
0.460
Volume
1.64M
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Psychedelic Stock Gainers And Losers From February 3, 2023
GAINERS:Seelos Therapeutics (NASDAQ:SEEL) shares closed up 7.00% at $0.87ATAI Life Sciences (NASDAQ:ATAI) shares closed up 6.52% at $1.96Cybin (AMEX:CYBN) shares closed up 4.38% at $0.46Compass Pathwa
'Change To Classification Of Psilocybin And MDMA To Enable Prescribing By Authorized Psychiatrists'; Australia Allows Prescription of MDMA and Psilocybin in Groundbreaking Regulatory Change - Australian Government Department Of Health And Aged Care
From 1 July this year, medicines containing the psychedelic substances psilocybin and MDMA (3,4-methylenedioxy-methamphetamine) can be prescribed by specifically authorised psychiatrists for the treat
Psychedelic Stock Gainers And Losers From February 1, 2023
GAINERS:Cybin (AMEX:CYBN) shares closed up 11.01% at $0.43ATAI Life Sciences (NASDAQ:ATAI) shares closed up 3.37% at $1.84Numinus Wellness (OTC:NUMIF) shares closed up 2.35% at $0.20GH Research (NASDA
'Psychedelics Bills Filed In Four More States As 2023 Reform Efforts Heat Up' -Marijuana Moment Report
'Psychedelics Bills Filed In Four More States As 2023 Reform Efforts Heat Up' -Marijuana Moment Report
Cybin Gets Regulatory OK to Begin Dosing Psychedelic-derived Drug in Humans
Cybin Announces Approval of First-in-Human Dosing of Its Proprietary DMT Molecule CYB004
- Marks first ever trial to evaluate deuterated DMT in humans – - Based on preclinical studies CYB004 demonstrated superior bioavailability compared to IV DMT which may support less invasive dosing me
Cybin Approved For First In-Human Dosing Of DMT Molecule CYB004, Milestone For Anxiety Disorder Treatment
Cybin Inc. (NYSE: CYBN) announced that it has received approval from an independent ethics committee in the Netherlands to begin the first in-human dosing of its proprietary deuterated N, N-dimethyltr
GH Research, Mind Medicine Among Top Psychedelic Movers Of Today
GAINERS:Mind Medicine (NASDAQ:MNMD) shares closed up 3.49% at $3.41Seelos Therapeutics (NASDAQ:SEEL) shares closed up 2.80% at $0.81ATAI Life Sciences (NASDAQ:ATAI) shares closed up 2.30% at $1.78Inte
Intelgenx Technologies, Cybin Among Top Psychedelic Movers Of Today
GAINERS:LOSERS:Intelgenx Technologies (OTC:IGXT) shares closed down 7.06% at $0.23Cybin (AMEX:CYBN) shares closed down 4.73% at $0.38Mind Medicine (NASDAQ:MNMD) shares closed down 4.22% at $3.29ATAI L
Cybin, GH Research Among Top Psychedelic Movers Of Today
GAINERS:GH Research (NASDAQ:GHRS) shares closed up 3.03% at $9.53LOSERS:Cybin (AMEX:CYBN) shares closed down 4.07% at $0.39Seelos Therapeutics (NASDAQ:SEEL) shares closed down 2.97% at $0.81ATAI Life
Company Overview
More
Cybin, Inc. is an ethical biopharmaceutical company engaged in the development of therapeutics for patients to address a multitude of mental health issues. It is focused on progressing psychedelics to therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and treatment regimens for mental health disorders. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.
CEO： Mr. Douglas Drysdale
Market： AMEX
Listing Date： 08/05/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet